By Ian Walker

Angle PLC shares rose as much as 41% in early trade after the company said that DNA molecular analysis from cancer patient blood samples provides insight into the progression and treatment of cancers for those patients, and enables it to expand product sales and pharmaceutical service offerings.

Shares at 0834 GMT were up 4.50 pence, or 34%, at 17.75 pence having peaked at 18.63 pence earlier in the session. However, they are down 63% over the past 12 months.

The U.K. liquid-biopsy company said Thursday that the results come from 47 patient samples in breast, lung, prostate and ovarian cancers.

"Today's breakthrough is the critical next step post the [Food and Drug Administration] clearance to show in a sample-to-answer format the potential clinical value of NGS [next generation sequencing] molecular analysis on a repeat basis of living cancer cells harvested from patient blood samples," Chief Executive Officer Andrew Newland said.

Write to Ian Walker at ian.walker@wsj.com

(END) Dow Jones Newswires

January 04, 2024 03:55 ET (08:55 GMT)

Copyright (c) 2024 Dow Jones & Company, Inc.
Angle (LSE:AGL)
Historical Stock Chart
From Mar 2024 to Apr 2024 Click Here for more Angle Charts.
Angle (LSE:AGL)
Historical Stock Chart
From Apr 2023 to Apr 2024 Click Here for more Angle Charts.